Al-Ejeh F - Search Results

1

APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.

Al-Ejeh F, Darby JM, Tsopelas C, Smyth D, Manavis J, Brown MP. Al-Ejeh F, et al. PLoS One. 2009;4(2):e4558. doi: 10.1371/journal.pone.0004558. Epub 2009 Feb 27. PLoS One. 2009. PMID: 19247492 Free PMC article.

2

The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.

Al-Ejeh F, Darby JM, Brown MP. Al-Ejeh F, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5509s-5518s. doi: 10.1158/1078-0432.CCR-07-0922. Clin Cancer Res. 2007. PMID: 17875783

3

In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.

Al-Ejeh F, Darby JM, Pensa K, Diener KR, Hayball JD, Brown MP. Al-Ejeh F, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5519s-5527s. doi: 10.1158/1078-0432.CCR-07-0964. Clin Cancer Res. 2007. PMID: 17875784

4

Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.

Al-Ejeh F, Darby JM, Brown MP. Al-Ejeh F, et al. PLoS One. 2009;4(2):e4630. doi: 10.1371/journal.pone.0004630. Epub 2009 Feb 27. PLoS One. 2009. PMID: 19247485 Free PMC article.

5

A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution.

Al-Ejeh F, Darby JM, Thierry B, Brown MP. Al-Ejeh F, et al. Nucl Med Biol. 2009 May;36(4):395-402. doi: 10.1016/j.nucmedbio.2009.01.001. Epub 2009 Mar 26. Nucl Med Biol. 2009. PMID: 19423007

6

Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.

Al-Ejeh F, Staudacher AH, Smyth DR, Darby JM, Denoyer D, Tsopelas C, Hicks RJ, Brown MP. Al-Ejeh F, et al. J Nucl Med. 2014 May;55(5):772-9. doi: 10.2967/jnumed.113.130559. Epub 2014 Mar 27. J Nucl Med. 2014. PMID: 24676755 Free article.

7

The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.

Staudacher AH, Al-Ejeh F, Fraser CK, Darby JM, Roder DM, Ruszkiewicz A, Manavis J, Brown MP. Staudacher AH, et al. EJNMMI Res. 2014 Jan 4;4(1):2. doi: 10.1186/2191-219X-4-2. EJNMMI Res. 2014. PMID: 24387284 Free PMC article.

8

Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.

Al-Ejeh F, Pajic M, Shi W, Kalimutho M, Miranda M, Nagrial AM, Chou A, Biankin AV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative; Brown MP, Khanna KK. Al-Ejeh F, et al. Clin Cancer Res. 2014 Jun 15;20(12):3187-97. doi: 10.1158/1078-0432.CCR-14-0048. Epub 2014 May 16. Clin Cancer Res. 2014. PMID: 24838526

9

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM. Pishas KI, et al. Clin Cancer Res. 2011 Feb 1;17(3):494-504. doi: 10.1158/1078-0432.CCR-10-1587. Epub 2010 Nov 23. Clin Cancer Res. 2011. PMID: 21098696

10

Immunotargeting of Functional Nanoparticles for MRI detection of Apoptotic Tumor Cells.

Thierry B, Al-Ejeh F, Brown MP, Majewski P, Griesser HJ. Thierry B, et al. Adv Mater. 2009 Feb 2;21(5):541-5. doi: 10.1002/adma.200800998. Adv Mater. 2009. PMID: 21161977 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters